2023-03-29 07:40:28 ET
- Medical device company ClearPoint Neuro ( NASDAQ: CLPT ) has signed an exclusive multi-year licensing agreement with UC San Francisco to develop and commercialize a brain-focused cellular delivery device.
- The intracerebral device is designed to help clinicians direct the delivery of biological therapies, such as stem cell transplants and gene therapy vectors, to specific sites in the brain based on fluoroscopy/CT and MRI guidance.
- “….I hope that this invention can contribute importantly to the successful treatment of neurological disorders such as Parkinson’s disease,” Dr. Daniel Lim, Professor of Neurological Surgery at UCSF, who designed the device, said.
- Per the terms, ClearPoint ( CLPT ) will be responsible for developing, seeking regulatory clearance, and product commercialization in key geographies.
- Read: Seeking Alpha contributor Amit Ghate highlighted ClearPoint’s ( CLPT ) business model, competitive advantages, and growth narrative in issuing a Buy rating on the stock in January.
For further details see:
ClearPoint inks licensing deal for cellular delivery device